Outlook Therapeutics Announces New Employment Inducement Grants

Q: What is the exercise price of the Outlook Therapeutics inducement options (OTLK)?

The announced options have a per‑share exercise price of $2.01 .

Q: Why were the stock options granted by Outlook Therapeutics (OTLK)?

The options were awarded as inducement grants to facilitate the two individuals entering into employment, in accordance with NASDAQ Rule 5635(c)(4).

Q: How many employees received inducement option awards from Outlook Therapeutics (OTLK)?

The awards were granted to two new employees .

Q: Will the 150,000 option grant for Outlook Therapeutics (OTLK) immediately dilute existing shareholders?

The announcement states the aggregate option amount ( 150,000 shares ) was granted; any dilution depends on option exercise timing and outstanding share count not disclosed in the announcement.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Very Positive)

Rhea-AI Summary

Outlook Therapeutics (Nasdaq: OTLK) announced on Dec 26, 2025 that, effective Dec 19, 2025, its Compensation Committee granted stock options to purchase an aggregate of 150,000 shares of common stock to two new employees.

The options carry a per‑share exercise price of $2.01 and were awarded as inducement grants under NASDAQ Listing Rule 5635(c)(4) to facilitate the employees entering into employment with the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

12/26/2025 - 05:00 PM

ISELIN, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that effective December 19, 2025, the Outlook Therapeutics, Inc. Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 150,000 shares of Outlook Therapeutics common stock with a per share exercise price of $2.01 per share to two new employees.

The above-described awards were granted as an inducement material to the employees entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retinal diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD (wet age-related macular degeneration). Outlook Therapeutics commenced the commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the treatment of wet AMD.

In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.

Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com

FAQ

What did Outlook Therapeutics (OTLK) announce on Dec 26, 2025 regarding employee equity?

The company said it granted stock options for an aggregate of 150,000 shares to two new employees, effective Dec 19, 2025.

What is the exercise price of the Outlook Therapeutics inducement options (OTLK)?

The announced options have a per‑share exercise price of $2.01.

Why were the stock options granted by Outlook Therapeutics (OTLK)?

The options were awarded as inducement grants to facilitate the two individuals entering into employment, in accordance with NASDAQ Rule 5635(c)(4).

How many employees received inducement option awards from Outlook Therapeutics (OTLK)?

The awards were granted to two new employees.

Will the 150,000 option grant for Outlook Therapeutics (OTLK) immediately dilute existing shareholders?

The announcement states the aggregate option amount (150,000 shares) was granted; any dilution depends on option exercise timing and outstanding share count not disclosed in the announcement.